Stock prices for Galderma, a Swiss-based skincare corporation, climbed Thursday morning following the company’s announcement of strong annual revenue performance and optimistic future projections.
The skincare giant reported annual revenue of $5.21 billion, representing a 17.7% increase from the previous year. The company’s Therapeutic Dermatology division led this impressive performance, with sales jumping more than 50% primarily due to its newly introduced Nemluvio treatment. This medication addresses chronic skin disorders including atopic dermatitis and prurigo nodularis.
Looking ahead to 2026, Galderma forecasts revenue growth between 17% and 20%, along with core profit margins reaching approximately 26% when calculated on a constant-currency basis.
By mid-morning trading, the company’s stock had climbed roughly 7%. Financial analysts from Vontobel noted that these projections surpassed market expectations, contributing to investor enthusiasm.
